½ÃÀ庸°í¼­
»óǰÄÚµå
1607234

¼¼°èÀÇ HLA ŸÀÌÇÎ ½ÃÀå : ±â¼ú, Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

HLA Typing Market by Technology (Molecular Assay Technologies, Non-Molecular Assay Technology), Products (Instruments, Reagents & Consumables, Software & Services), Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

HLA ŸÀÌÇÎ ½ÃÀåÀº 2023³â¿¡ 145¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 152¾ï 8,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.36%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 209¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àΰ£ ¹éÇ÷±¸ Ç׿ø(HLA)ÀÇ µ¹¿¬º¯À̸¦ °áÁ¤ÇÏ´Â °úÁ¤ÀÎ HLA ŸÀÌÇÎÀº ÁÖ·Î Àå±â À̽Ä, ºÎÀÚ °¨Á¤, Áúº´ °ü·Ã ¿¬±¸ µî ¿©·¯ ÀÇ·á ¿ëµµ¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. HLA ŸÀÌÇÎÀÇ Çʿ伺Àº Àå±â ±âÁõÀÚ¿Í ¼ö·ÉÀÎÀ» ÀÏÄ¡½Ã۰í ÀÌ½Ä °ÅºÎ ¹ÝÀÀÀÇ À§ÇèÀ» Å©°Ô ÁÙÀÌ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. ±×¸®°í ƯÁ¤ Áúº´ÀÇ À¯Àü Àû ¼ÒÀÎÀ» ÀÌÇØÇÏ´Â °Íµµ È®ÀåµË´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚ´Â ÁÖ·Î º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿¬±¸ ±â°üÀÔ´Ï´Ù. ±¸¿Í ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ°ú °°Àº HLA ŸÀÌÇÎ ±â¼úÀÇ Áøº¸°¡ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÔ´Ï´Ù. ºñÁî´Ï½º ±âȸ´Â ¹Ì°³Ã´ ½ÅÈï ½ÃÀå°ú Çõ½ÅÀûÀÎ ºñ ħ½ÀÀû HLA ŸÀÌÇÎ ¹æ¹ý¿¡ ÀÖÀ¸¸ç, À̴ ȯÀÚÀÇ Ä¡·á¸¦ ¿ëÀÌÇϰÔÇϰí Á¤È®¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ´Â ºñ¿ë È¿À²ÀûÀÌ°í ½Ã°£ È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀÇ °³¹ß°ú °ß°íÇÑ Àü·«Àû Á¦ÈÞ¸¦ ¿ì¼± ÇÒ ¼ö ÀÖ½À´Ï´Ù, ±×·¯³ª ½ÃÀåÀº ³ôÀº ¿î¿µ ºñ¿ë, ±â¼úÀû º¹À⼺, ¾ö°ÝÇÑ ±ÔÁ¦. ȯ°æ µîÀÇ Á¦¾à¿¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, À̰ÍÀÌ ¼ºÀåÀÇ ±â¼¼¸¦ ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´À» ´õ¿í º¹ÀâÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.»õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¸¦ ޱ¸ÇÏ°í °Ë»ç ÇÁ·ÎÅäÄÝÀ» ´Ü¼øÈ­Çϱâ À§ÇÑ R&D ÀÌ´Ï¼ÅÆ¼ºê¸¦ ´Ù·ç´Â °Íµµ À¯ÀÍÇÕ´Ï´Ù. ±â¾÷Àº ±Þ¼Óµµ·Î ¹ßÀüÇÏ´Â ¿µ¿ª¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇϰí Áö¼Ó °¡´ÉÇÑ ¼ºÀåÀ» °¡¼ÓÇϱâ À§ÇØ ±â¼úÀû º¯È­¿Í ÁøÈ­ÇÏ´Â ÀÇ·á Á¤Ã¥¿¡ Áö¼ÓÀûÀ¸·Î ÀûÀÀÇÏ°í ¹Îø¼ºÀ» À¯ÁöÇØ¾ßÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 145¾ï 4,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 152¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 209¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 5.36%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â HLA ŸÀÌÇÎ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

HLA ŸÀÌÇÎ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Ç¥Àû ¿¬±¸ Ȱµ¿¿¡ ´ëÇÑ °ü¹Î ÀÚ±Ý Áõ°¡
    • °íÇüÀå±â ÀÌ½Ä Áõ°¡¿Í ³ëÀÎ Àα¸ È®´ë
    • °¨¿°ÁõÀÇ À¯Çà°ú °ñ¼ö¡¤Ç÷¾× À̽ÄÀÇ ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • HLA ŸÀÌÇÎ ÀýÂ÷ÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • PCR¿¡ ±âÃÊÇÑ HLA ŸÀÌÇιýÀÇ ÁøÀü
    • ÀÌ½Ä Áø´Ü ºÐ¾ß¿¡ À־ÀÇ ±â¼úÀÇ Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • HLA ŸÀÌÇÎÀÇ ºÎÁ¤È®¼º¿¡ ´ëÇÑ ¿ì·Á

Porter's Five Force : HLA ŸÀÌÇÎ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : HLA ŸÀÌÇÎ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº HLA ŸÀÌÇÎ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : HLA ŸÀÌÇÎ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

HLA ŸÀÌÇÎ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ½ÃÀåÀÇ ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­ÇÏ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : HLA ŸÀÌÇÎ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â HLA ŸÀÌÇÎ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : HLA ŸÀÌÇÎ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

HLA ŸÀÌÇÎ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ´ë»ó Á¶»ç Ȱµ¿¿¡ ´ëÇÑ °ü¹Î ÀÚ±Ý Áõ°¡
      • °íÇüÀå±â ÀÌ½Ä Áõ°¡¿Í ³ëÀÎ Àα¸ È®´ë
      • °¨¿°ÁõÀÇ ¸¸¿¬°ú °ñ¼ö¡¤Ç÷¾× ÀÌ½Ä °Ç¼öÀÇ ±ÞÁõ
    • ¾ïÁ¦¿äÀÎ
      • HLA ŸÀÌÇÎ ÀýÂ÷ÀÇ ºñ¿ëÀÌ ³ô´Ù
    • ±âȸ
      • PCR ±â¹ÝÀÇ HLA ŸÀÌÇιýÀÇ Áøº¸
      • ÀÌ½Ä Áø´Ü ºÐ¾ß¿¡ À־ÀÇ ±â¼úÀÇ Áøº¸
    • °úÁ¦
      • HLA ŸÀÌÇÎÀÇ ºÎÁ¤È®¼º¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå HLA ŸÀÌÇÎ ½ÃÀå : ±â¼úº°

  • ºÐÀÚ ºÐ¼® ±â¼ú
  • ºñºÐÀÚ ºÐ¼® ±â¼ú

Á¦7Àå HLA ŸÀÌÇÎ ½ÃÀå : Á¦Ç°º°

  • ±â±â
  • ½Ã¾à ¹× ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

Á¦8Àå HLA ŸÀÌÇÎ ½ÃÀå : ¿ëµµº°

  • Áø´Ü ¿ëµµ
  • Á¶»ç ¿ëµµ

Á¦9Àå HLA ŸÀÌÇÎ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú±â°ü
  • º´¿ø°ú ÀÌ½Ä ¼¾ÅÍ
  • µ¶¸³ ±âÁØ ½ÇÇè½Ç
  • ¿¬±¸½Ç

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ HLA ŸÀÌÇÎ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ HLA ŸÀÌÇÎ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ HLA ŸÀÌÇÎ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Becton, Dickinson, and Company
  • BGI Group
  • Bio-Rad Laboratories
  • CareDx, Inc.
  • Creative Biolabs, Inc.
  • F. Hoffman-La Roche Limited
  • Fujirebio Diagnostics, Inc.
  • Genome Diagnostics Pvt. Ltd.
  • Histogenetics India Pvt Ltd
  • Illumina, Inc.
  • Immucor, Inc.
  • Pacific Biosciences of California, Inc.
  • TAKARA BIO INC.
  • Thermo Fisher Scientific
JHS 24.12.17

The HLA Typing Market was valued at USD 14.54 billion in 2023, expected to reach USD 15.28 billion in 2024, and is projected to grow at a CAGR of 5.36%, to USD 20.97 billion by 2030.

HLA typing, the process of determining human leukocyte antigen (HLA) variations, plays a pivotal role in several medical applications, primarily in organ transplantation, paternity testing, and disease association studies. The necessity of HLA typing lies in its ability to match organ donors with recipients, significantly reducing transplant rejection risks. Its applications extend into identifying potential autoimmune conditions and understanding the genetic predispositions for certain diseases. End-users primarily include hospitals, diagnostic laboratories, and research institutions. Market insights reveal that increasing demand for organ transplants, coupled with advancements in HLA typing technologies like next-generation sequencing and polymerase chain reaction, are key growth influencers. Additionally, rising public awareness and healthcare funding bolster market expansion opportunities. Potential opportunities lie in untapped emerging markets and innovative non-invasive HLA typing methods, which can ease patient procedures and enhance accuracy. To capitalize on these opportunities, companies could prioritize developing cost-effective, time-efficient solutions and solid strategic collaborations. However, the market faces limitations such as high operational costs, technical complexities, and stringent regulatory environments, which impede growth momentum. Challenges like limited access to advanced healthcare facilities in developing regions and the need for highly skilled personnel further complicate market expansion. Innovation and research should focus on improving typing accuracy, reducing testing time, and integrating AI and machine learning to enhance predictive analytics in patient care. Engaging in R&D initiatives to explore new biomarkers and simplifying the testing protocols could also prove beneficial. The nature of the HLA typing market is dynamic, driven by technological advancements and expanding healthcare needs. Companies must remain agile, continuously adapting to technological changes and evolving healthcare policies, to maintain competitiveness and foster sustainable growth within this rapidly progressing domain.

KEY MARKET STATISTICS
Base Year [2023] USD 14.54 billion
Estimated Year [2024] USD 15.28 billion
Forecast Year [2030] USD 20.97 billion
CAGR (%) 5.36%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HLA Typing Market

The HLA Typing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing public-private funding for target research activities
    • Increasing number of solid organ transplants and expanding geriatric population
    • Rising prevalence of infectious diseases and soaring number of bone marrow and blood transplant processes
  • Market Restraints
    • High cost of HLA typing procedures
  • Market Opportunities
    • Progressive developments of PCR-based HLA-typing methods
    • Technological advancements in the field of transplant diagnostics
  • Market Challenges
    • Concerns regarding inaccuracy of HLA typing

Porter's Five Forces: A Strategic Tool for Navigating the HLA Typing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HLA Typing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HLA Typing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HLA Typing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HLA Typing Market

A detailed market share analysis in the HLA Typing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HLA Typing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HLA Typing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HLA Typing Market

A strategic analysis of the HLA Typing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing Market, highlighting leading vendors and their innovative profiles. These include Becton, Dickinson, and Company, BGI Group, Bio-Rad Laboratories, CareDx, Inc., Creative Biolabs, Inc., F. Hoffman-La Roche Limited, Fujirebio Diagnostics, Inc., Genome Diagnostics Pvt. Ltd., Histogenetics India Pvt Ltd, Illumina, Inc., Immucor, Inc., Pacific Biosciences of California, Inc., TAKARA BIO INC., and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the HLA Typing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technology.
  • Based on Products, market is studied across Instruments, Reagents & Consumables, and Software & Services.
  • Based on Application, market is studied across Diagnostic Applications and Research Applications.
  • Based on End-User, market is studied across Academic Institutes, Hospitals & Transplant Centers, Independent Reference Laboratories, and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing public-private funding for target research activities
      • 5.1.1.2. Increasing number of solid organ transplants and expanding geriatric population
      • 5.1.1.3. Rising prevalence of infectious diseases and soaring number of bone marrow and blood transplant processes
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of HLA typing procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Progressive developments of PCR-based HLA-typing methods
      • 5.1.3.2. Technological advancements in the field of transplant diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns regarding inaccuracy of HLA typing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HLA Typing Market, by Technology

  • 6.1. Introduction
  • 6.2. Molecular Assay Technologies
  • 6.3. Non-Molecular Assay Technology

7. HLA Typing Market, by Products

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
  • 7.4. Software & Services

8. HLA Typing Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Applications
  • 8.3. Research Applications

9. HLA Typing Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic Institutes
  • 9.3. Hospitals & Transplant Centers
  • 9.4. Independent Reference Laboratories
  • 9.5. Research Laboratories

10. Americas HLA Typing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific HLA Typing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa HLA Typing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Becton, Dickinson, and Company
  • 2. BGI Group
  • 3. Bio-Rad Laboratories
  • 4. CareDx, Inc.
  • 5. Creative Biolabs, Inc.
  • 6. F. Hoffman-La Roche Limited
  • 7. Fujirebio Diagnostics, Inc.
  • 8. Genome Diagnostics Pvt. Ltd.
  • 9. Histogenetics India Pvt Ltd
  • 10. Illumina, Inc.
  • 11. Immucor, Inc.
  • 12. Pacific Biosciences of California, Inc.
  • 13. TAKARA BIO INC.
  • 14. Thermo Fisher Scientific
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦